Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Cinoxacin was administered to 30 outpatients with chronic complicated urinary tract infection for 57.3 days (average) and the following results were obtained. Clinical efficacy based on decrease of pyuria were "excellent" in 44.8%, "good" in 31.0%, "fair" in 24.1%, and "poor" in 0%; and, overall effectiveness rate reached 75.9%. As for side effect, diarrhea and nausea were observed in 2 and 1 patients, respectively. GOT and GPT elevation was also seen in one case. Cinoxacin long term therapy seems to be effective and useful to chronic complicated urinary tract infections.
 ...
PMID:[Clinical study on long-term cinoxacin therapy for outpatients with chronic complicated urinary tract infections]. 405 Jun 34

Cinoxacin, a chemotherapeutic agent that inhibits bacterial DNA synthesis, has recently been approved for the treatment of initial and recurrent bacterial urinary tract infections. Although closely related to nalidixic acid, cinoxacin possesses some distinct characteristics: rapid attainment of therapeutic urinary concentrations and greater activity against strains of Enterobacteriaceae that cause urinary tract infections. Biopharmaceutical properties include serum protein binding of approximately 70%, 50-60% excretion of intact drug in the urine of patients with normal renal function, and an elimination half-life of approximately one hour. The elimination half-life is increased in patients with decreased renal function and when probenecid is coadministered. Adverse events occur infrequently and consist of nausea, vomiting, headache, dizziness, and hypersensitivity reactions. The drug compares favorably with standard therapies for the treatment of bacterial cystitis and recurrent urinary tract infections. Initial studies demonstrate that cinoxacin has substantial efficacy as a prophylactic agent for those women who experience recurrent, symptomatic urinary tract infections.
 ...
PMID:Cinoxacin: mechanism of action, spectrum of activity, pharmacokinetics, adverse reactions, and therapeutic indications. 676 8

The urinary antibacterial drugs cinoxacin (Cinobac) and nitrofurantoin (Macrodantin) were compared for efficacy and side effects in the treatment of uncomplicated lower urinary tract infections occurring in elderly patients admitted to a rehabilitation hospital. Twenty-five patients received cinoxacin and 27 received nitrofurantoin for an average of thirteen days' treatment. The antibacterial spectrum of cinoxacin was noted to be better than that of nitrofurantoin, but both drugs performed well in clearing the infections caused by susceptible organisms. There were no side effects from cinoxacin therapy, but 15 per cent of patients receiving the nitrofurantoin experienced anorexia and nausea, in some cases sufficiently severe to require early termination of therapy.
 ...
PMID:A comparative drug study of lower urinary tract infections in elderly patients. 723 73